132 related articles for article (PubMed ID: 8736497)
1. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody.
Holliger P; Brissinck J; Williams RL; Thielemans K; Winter G
Protein Eng; 1996 Mar; 9(3):299-305. PubMed ID: 8736497
[TBL] [Abstract][Full Text] [Related]
2. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
Kipriyanov SM; Moldenhauer G; Strauss G; Little M
Int J Cancer; 1998 Aug; 77(5):763-72. PubMed ID: 9688311
[TBL] [Abstract][Full Text] [Related]
3. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
4. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris.
FitzGerald K; Holliger P; Winter G
Protein Eng; 1997 Oct; 10(10):1221-5. PubMed ID: 9488147
[TBL] [Abstract][Full Text] [Related]
5. Production and characterization of bispecific single-chain antibody fragments.
De Jonge J; Brissinck J; Heirman C; Demanet C; Leo O; Moser M; Thielemans K
Mol Immunol; 1995 Dec; 32(17-18):1405-12. PubMed ID: 8643110
[TBL] [Abstract][Full Text] [Related]
6. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
Le Gall F; Reusch U; Little M; Kipriyanov SM
Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas.
Helfrich W; Kroesen BJ; Roovers RC; Westers L; Molema G; Hoogenboom HR; de Leij L
Int J Cancer; 1998 Apr; 76(2):232-9. PubMed ID: 9537586
[TBL] [Abstract][Full Text] [Related]
8. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes.
Korn T; Müller R; Kontermann RE
J Immunother; 2004; 27(2):99-106. PubMed ID: 14770081
[TBL] [Abstract][Full Text] [Related]
9. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
10. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
11. Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.
Wei L; Dongmei F; Ming Y; Ruizan S; Yan Y; Linlin J; Cihui Y; Shuangjing L; Min W; Jianxiang W; Dongsheng X
Cell Oncol (Dordr); 2012 Dec; 35(6):423-34. PubMed ID: 23055339
[TBL] [Abstract][Full Text] [Related]
12. A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL.
Jost CR; Titus JA; Kurucz I; Segal DM
Mol Immunol; 1996 Feb; 33(2):211-9. PubMed ID: 8649442
[TBL] [Abstract][Full Text] [Related]
13. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
[TBL] [Abstract][Full Text] [Related]
14. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
[TBL] [Abstract][Full Text] [Related]
15. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
16. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
17. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
18. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
[TBL] [Abstract][Full Text] [Related]
19. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
20. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]